- Travere Therapeutics to Report First Quarter 2024 Financial Results
- Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
- Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
- Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
- Travere Therapeutics to Present at Upcoming Investor Conferences
- Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
- Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
- Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
More ▼
Key statistics
On Friday, Travere Therapeutics Inc (TVTX:NMQ) closed at 6.26, 22.27% above the 52 week low of 5.12 set on Apr 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.44 |
---|---|
High | 6.56 |
Low | 6.18 |
Bid | 4.00 |
Offer | 6.95 |
Previous close | 6.26 |
Average volume | 1.52m |
---|---|
Shares outstanding | 76.11m |
Free float | 75.20m |
P/E (TTM) | -- |
Market cap | 476.44m USD |
EPS (TTM) | -4.98 USD |
Data delayed at least 15 minutes, as of May 03 2024 21:00 BST.
More ▼